Back to the overview page

David (DE) Schmidt MD

Department
Experimental Immunohematology
E-mail
d.schmidt@sanquin.nl
LinkedIn
https://www.linkedin.com/in/schmidtdav
Training

Biomedical Sciences, Clinical Medicine, Medical Statistics

Research interests
Personalisation of the treatment of immune thrombocytopenia (ITP). We are striving to explain bleeding symptoms, heterogeneity in response to intravenous immunoglobulin (IVIG) therapy, and the variable disease trajectories of childhood ITP including the development of chronic disease. To do so, we study pharmacokinetic and genetic factors, serology for platelet autoantibodies, T- and B-cell immunology, and antibody effector functions.
Technology
Biostatistics and Epidemiology, Anti-platelet antibody effector assays, Diagnostic tests for anti-platelet antibodies
Resume
 2016-present Physician-Investigator, Department of Experimental Immunohematology,Sanquin Sanquin Research and Landsteiner Laboratory, University of Amsterdam and PhD candidate at Leiden University Medical Center
2016 Research trainee at Karolinska Institutet, Stockholm/Sweden
2016 Research trainee in Clinical Immunology/Transfusion Medicine and Hematology Center, Department of Medicine, Karolinska Institutet, Stockholm/Sweden
2012-2016 Scholarship, German National Academic Merit Foundation (Studienstiftung des Deutschen Volkes)
2012-2016

MD/MSc, Clinician Scientist Training Program (SUMMA), Utrecht University

with stays abroad at University Hospital Hamburg-Eppendorf (UKE), Germany and McMaster University, Hamilton/Canada
2009-2012

BSc Biomedical Sciences, Maastricht University

Publications
Sanquin publications
Other publications

Schmidt DE, Bruzelius M, Majeed A, Odeberg J, Holmström M, Ågren A. Whole blood ristocetin-activated platelet impedance aggregometry (Multiplate) for the rapid detection of Von Willebrand disease.Thromb Haemost. 2017;117(8). doi: 10.1160/TH17-02-0129. [Epub ahead of print]

Schmidt DE, Halmin M, Wikman A, Östlund A, Ågren A. Relative effects of plasma, fibrinogen concentrate, and factor XIII on ROTEM coagulation profiles in an in vitro model of massive transfusion in trauma.Scand J Clin Lab Invest. 2017:1-9. doi: 10.1080/00365513.2017.1334128. [Epub ahead of print]

Schmidt DE, Majeed A, Bruzelius M, Odeberg J, Holmström M, Ågren A. A prospective diagnostic accuracy study evaluating rotational thromboelastometry and thromboelastography in 100 patients with von Willebrand disease.Haemophilia. 2017;23(2):309-318. doi: 10.1111/hae.13121. Epub 2016 Oct 26.

Ågren A, Holmström M, Schmidt DE, Hosokawa K, Blombäck M, Hjemdahl P. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.Thromb Haemost. 2017;117(1):75-85. doi: 10.1160/TH16-06-0430. Epub 2016 Oct 20.

Versteylen MO, Manca M, Joosen IA, Schmidt DE, Das M, Hofstra L, Crijns HJ, Biessen EA, Kietselaer BL. CC chemokine ligands in patients presenting with stable chest pain: association with atherosclerosis and future cardiovascular events. Neth Heart J. 2016;24(12):722-729.

Schmidt DE, Manca M, Hoefer IE. Circulating endothelial cells in coronary artery disease and acute coronary syndrome. Trends Cardiovasc Med. 2015;25(7):578-87. doi: 10.1016/j.tcm.2015.01.013. Epub 2015 Feb 7. Review.

Schmidt DE, Holmström M, Majeed A, Näslin D, Wallén H, Ågren A.Detection of elevated INR by thromboelastometry and thromboelastography in warfarin treated patients and healthy controls. Thromb Res. 2015;135(5):1007-11. doi: 10.1016/j.thromres.2015.02.022. Epub 2015 Feb 26.

Schmidt DE, Steinhagen F, Schnabel C, Spath B, Holstein K, Fiedler W, Bokemeyer C, Renné T, Langer F. Thrombin generation in a patient with an acquired high-titre factor V inhibitor. Blood Coagul Fibrinolysis. 2015;26(1):81-7. doi: 10.1097/MBC.0000000000000181.

Last edited on: 19 July 2017
Back to the overview page